Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | JAK3 | P52333 | 3/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | CD38 | P28907 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 9/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.40 |
| ▸ | KRAS | P01116 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 4/20 | 0.39 |
| ▸ | RET | P07949 | 4/20 | 0.39 |
| ▸ | KIF5B | P33176 | 2/20 | 0.39 |
| ▸ | GAK | O14976 | 1/20 | 0.38 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
| ▸ | STK10 | O94804 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1707249 | 0.79 | EGFR (0.58) | LMNAHTTSMN1; SMN2JAK3ABCB1 | |
| SCHEMBL1706562 | 0.79 | LMNA (0.51) | LMNAHTTSMN1; SMN2JAK3CD38 | |
| SCHEMBL1755277 | 0.79 | LMNA (0.58) | LMNAHTTSMN1; SMN2JAK3ABCB1 | |
| SCHEMBL1707037 | 0.78 | LMNA (0.50) | LMNAHTTSMN1; SMN2JAK3CD38 | |
| SCHEMBL12935442 | 0.78 | LMNA (0.50) | LMNAHTTSMN1; SMN2JAK3CD38 | |
| SCHEMBL1708313 | 0.78 | LMNA (0.54) | LMNAHTTSMN1; SMN2JAK3CD38 | |
| SCHEMBL2285944 | 0.76 | HTT (1.00) | LMNAHTTSMN1; SMN2CD38ALK | |
| SCHEMBL1755322 | 0.75 | LMNA (0.47) | LMNAHTTSMN1; SMN2JAK3CD38 | |
| SCHEMBL1707023 | 0.75 | HTT (0.56) | LMNAHTTSMN1; SMN2JAK3ABCG2 | |
| SCHEMBL27409854 | 0.74 | LMNA (0.59) | LMNAHTTSMN1; SMN2CD38EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247579-B1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNOMODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | Bayer Pharma AG (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-7863283-B2 | Sulphoximine-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2011-01-04 | — | — | US | disclosed |
| US-7863283-B2 | Sulphoximine-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2011-01-04 | — | — | US | disclosed |
| US-7863283-B2 | Sulphoximine-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2011-01-04 | — | — | US | disclosed |
| EP-2247579-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNOMODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009089851-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNOMODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-23 | — | — | WO | disclosed |
| US-20090186911-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNO-MODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| US-20090186911-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNO-MODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| US-20090186911-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNO-MODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186911-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNO-MODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | IFNG, TPMT, IRF3 | LMNA 4882/4885HTT 3954/4885SMN1; SMN2 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.